title: Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide.
authors.forename: M
authors.initials: M
authors.lastname: Horowitz
authors.forename: T
authors.initials: T
authors.lastname: Vilsbøll
authors.forename: M
authors.initials: M
authors.lastname: Zdravkovic
authors.forename: M
authors.initials: M
authors.lastname: Hammer
authors.forename: S
authors.initials: S
authors.lastname: Madsbad
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D052216:Glucagon-Like Peptide 1 / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D054795:Incretins / Q000009:adverse effects*; D000069450:Liraglutide; D008297:Male; D008875:Middle Aged
chemical_list: D054795:Incretins; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1